RT Journal Article
SR Electronic
T1 Cholesterol Metabolism—Impacts on SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20068528
DO 10.1101/2020.04.16.20068528
A1 Wei, Congwen
A1 Wan, Luming
A1 Zhang, Yanhong
A1 Fan, Chen
A1 Yan, Qiulin
A1 Yang, Xiaoli
A1 Gong, Jing
A1 Yang, Huan
A1 Li, Huilong
A1 Zhang, Jun
A1 Zhang, Zhe
A1 Wang, Rong
A1 Wang, Xiaolin
A1 Sun, Jin
A1 Zong, Yulong
A1 Yin, Feng
A1 Zhang, Rui
A1 Gao, Qi
A1 Cao, Yuan
A1 Zhong, Hui
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.16.20068528.abstract
AB The recently emerged pathogenic SARS-coronavirus 2 (SARS-CoV-2) has spread rapidly, leading to a global pandemic. In this study, we show that SARS-CoV-2 infection was associated with clinically significant lower level of HDL cholesterol (HDL-C), which can be used as indicators of disease severity and poor prognosis. Importantly, we found the spike protein of SARS-CoV-2 (SARS-2-S) bound to HDL. Antagonists of HDL receptor-Scavenger receptor class B type I (SR-B1), strongly inhibited SARS-CoV-2 infection. Notably, the lipids transfer function of SR-B1 was indispensable for this inhibition, offering explanations for the reduced serum HDL level observed in COVID-19 patients. Basing on findings here, we speculate that SR-B1-mediated pulmonary HDL-vitamin E uptake could participate in mediating SARS-CoV-2 infection of lung cells, and the unique expression profile of SR-B1 may also affect SARS-CoV-2 cell and tissue tropism. These findings might help to provide further insights into viral transmission, pathological characteristics and reveal therapeutic targets.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a single center based retrospective study, not a clinical trialFunding StatementThis study was supported in part by grants from the National Key Research and Development Program of China (2018YFA0900800) and the National Natural Science Foundation of China (31670761, 31872715 and 81773205).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data, models, or code generated or used during the study are available from the corresponding author by request.